What is QuantumCyte?
QuantumCyte specializes in precision diagnostics, leveraging its proprietary QCPRECISE platform to transform tissue slides into high-purity molecular samples. This technology enhances clarity and confidence in diagnostic results, serving both clinical and pharmaceutical sectors. By reducing costs, accelerating research, and improving data quality for biomarker discovery and targeted therapy development, QuantumCyte aims to advance precision medicine. Their integrated approach combines image-based annotation with molecular testing, ensuring high cellular purity and diagnostic accuracy, even from low-content biopsies. The company's solutions are trusted by leading institutions, including Singapore General Hospital.
How much funding has QuantumCyte raised?
QuantumCyte has raised a total of $70K across 1 funding round:
Debt
$70K
Debt (2021): $70K with participation from PPP
What's next for QuantumCyte?
With significant Series B/C stage investment, QuantumCyte is poised for substantial growth and scaling. The recent influx of expansion capital is expected to fuel further development of its QCPRECISE platform, enhance market penetration within the clinical and pharmaceutical sectors, and potentially broaden its applications in biomarker discovery and targeted therapy. This strategic financing will likely support operational expansion, R&D initiatives, and the strengthening of its market position as a key player in precision diagnostics.
See full QuantumCyte company page
